PATH said it launched a project “to facilitate global access to new adjuvants and formulation technologies, aiming to accelerate the development and introduction of critical, lifesaving vaccines.” PATH said that funding is being provided by the Bill & Melinda Gates Foundation and involves collaboration with key technology partners including the Vaccine Formulation Laboratory at the University of Lausanne (UNIL) in Switzerland.” The project will focus on providing “industry-quality adjuvants and developing adjuvant-vaccine formulations that enhance immune response, reduce dose requirements, and decrease vaccine costs.” As part of the project, “PATH and partners will focus on evaluating novel adjuvants for potential use in the development of an effective and affordable adjuvanted formulation of inactivated polio vaccine (IPV). In collaboration with UNIL and other Bill & Melinda Gates Foundation–funded research teams, PATH will also work to develop multiple formulations of IPV with other adjuvants. A later phase of the project may involve the development of adjuvanted formulations for vaccines against malaria, rotavirus, AIDS, or tuberculosis. Throughout, PATH will work to foster synergies and strategic partnerships that facilitate the development and advancement of future formulations through efforts that might involve securing access to advanced industry-quality adjuvants and the transfer of technology, data, and expertise among adjuvant developers, product-development partnerships, vaccine producers, and other stakeholders.”

http://www.path.org/news/pr120514-vaccine-access.php